A washout period is a period defined in the protocol between treatment phases or before the start of study treatment, during which the effect of a previous therapy is intended to subside. It is primarily used in crossover studies to prevent the treatment of one period from influencing the results of the subsequent period.
Purpose of the washout period
The central purpose is to limit a carry-over effect. This refers to the residual effect of a previously administered treatment that still influences the endpoint during the subsequent treatment period. Such an effect can be pharmacokinetic, pharmacodynamic, or disease-related. A medicinal product may, for instance, still be present in the body, trigger a persistent biological effect, or alter the clinical condition in such a way that a later comparison can no longer be attributed to the new treatment alone.
The duration of the washout period must be appropriate to the active substance class, the endpoint, the disease, and safety aspects. A pharmacokinetic half-life can be a relevant indicator, but is not always sufficient. The decisive factor is when a clinically or biologically relevant influence on the subsequent measurement is no longer to be expected. In the case of long-lasting effects, irreversible effects, or a variable disease course, a washout period can be insufficient or ethically problematic; a crossover design may then not be suitable.
Planning and conduct
The protocol should define the purpose, duration, permitted and prohibited concomitant treatments, monitoring measures, and stopping rules. For a washout period prior to randomization, it must be explained why the previous treatment is discontinued and how care and safety remain ensured. Between two treatment periods, it must also be clear when the new period begins and how adherence to the washout period is documented. The handling of unpermitted concomitant medication, early discontinuations, and missing measurements belongs in the statistical analysis plan.
Data collection should allow an assessment of whether relevant effects of the previous period have subsided. Depending on the question, this can include clinical parameters, laboratory values, or concentration measurements. Randomization of the treatment sequence, a suitable control group, and the most objective endpoints possible limit additional biases. Blinding can also be helpful, but does not replace an appropriate washout period. It prevents knowledge of the allocation, not the residual biological effect of a previous treatment.
Differentiation from the crossover study
The washout period is a component, not the entire crossover study. In a crossover study, the same participants sequentially receive different treatments in a previously randomized order. This allows participants to serve as their own control. The washout period lies between the periods and is intended to ensure the comparability of these consecutive treatments. The separate entry crossover study describes the complete design; this entry explains its temporal protective phase.
Therefore, not every study with a treatment interruption is a crossover study or contains a washout period. A treatment pause or follow-up period can have other purposes, such as capturing safety or preparing for a new therapy. Characteristic of a washout period is the a priori justified expectation that confounding effects of the previous treatment have sufficiently subsided before the subsequent comparison. The carry-over effect is the methodological risk that this phase is intended to limit.
Carry-over effects can also occur when the active substance itself can hardly be measured anymore. A previous treatment can alter disease activity, biomarkers, or sensitivity to subsequent therapy in the long term. Therefore, not only the medicinal product concentration is considered. The justification must explain why the chosen duration is sufficient for the specific endpoint and which data support this assumption. In case of uncertainty, alternative designs or analyses are to be considered.
Relevance for clinical trials
An inappropriate washout period can bias the estimation of the treatment effect and leave the study question unanswered. Too short periods cannot prevent carry-over effects; too long periods can unnecessarily leave participants without effective treatment, complicate recruitment, or lead to dropouts. The justification must therefore consider clinical safety and methodological validity together. Missing data and dropouts during the phase are just as relevant for interpretation as adherence to the rules.
Full-service CROs such as Mediconomics support the protocol planning of treatment periods, washout rules, and safety monitoring, as well as the coordination with biostatistics, data management, and monitoring. Concrete services include defining permitted concomitant medication, designing data collection time points, training the study sites, checking protocol adherence, and statistically evaluating potential period, sequence, and carry-over effects.
Frequently Asked Questions (FAQ)
How long must a washout period be?
There is no universally valid duration. It is justified in the protocol based on duration of effect, pharmacokinetics, pharmacodynamic effects, disease, endpoint, and safety aspects.
Does blinding prevent a carry-over effect?
No. Blinding limits information and assessment biases. A carry-over effect is a continuing biological or clinical effect of a previous treatment.
Why can a washout period be ethically critical?
During a treatment pause, an effective therapy could be lacking or a disease could progress. Therefore, scientific benefit, available care, and safety measures must be carefully weighed.
Regulatory references
- ICH E10 “Choice of Control Group and Related Issues” – covers design features including run-in periods in comparative studies.
- ICH E8(R1) “General Considerations for Clinical Studies” – requires a scientifically justified protocol and quality-critical factors in planning.
- ICH E9 “Statistical Principles for Clinical Trials” – basis for planning analyses and limiting biases.
- Regulation (EU) No 536/2014 – requires the protection of clinical trial subjects and the reliability of study data.